Ottawa – The latest edition of Meds Pipeline Monitor, from the Patented Medicine Prices Review Board, provides stakeholders with a list of new medicines in the late stages of clinical evaluation that may significantly impact clinical practice or drug spending in the coming years. There were over 12,000 drugs in the pipeline in 2023, increasing by an average of 19% per year since 2019.
Oncology represented one third (33%) of medicines in all phases of clinical trials. Treatments for infectious diseases and central nervous system diseases held the second and third largest share of the pipeline.
The Meds Pipeline Monitor focuses on novel medicines undergoing Phase III clinical trials or in pre-registration with the US Food and Drug Administration (FDA) in 2023. It also includes information on other drugs in Phase II that share the same mechanism of action or indication.
This edition of the report also highlights a list of potentially significant new medicines currently under review by Health Canada.